Needham Maintains Buy on Sarepta Therapeutics, Raises Price Target to $93
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $82 to $93.
November 02, 2023 | 10:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has maintained a Buy rating on Sarepta Therapeutics and raised the price target from $82 to $93, indicating a positive outlook for the company.
The raised price target by Needham analyst indicates a positive outlook for Sarepta Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100